Novel therapeutic modality for metastatic bone disease of breast cancer via hyaluronan inhibition
| Project/Area Number |
20591751
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
NISHIDA Yoshihiro Nagoya University, 医学系研究科, 准教授 (50332698)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSUKUSHI Satoshi 名古屋大学, 医学部附属病院, 病院助教 (90378109)
WASA Junji 名古屋大学, 医学部附属病院, 医員 (80547539)
細野 幸三 名古屋大学, 医学部附属病院, 医員 (40402599)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 糖鎖 / 乳癌 / 骨転移 / ヒアルロン酸 / 保存的治療 |
|---|
| Research Abstract |
4-MU (4-methylumbelliferone), an inhibitor for hyaluronan synthesis, and hyaluronan oligosaccharides, which has shown to suppress endogenous hyaluronan, effectively showed anti-tumor effect on breast and lung cancer. Moreover, these reagents significantly suppressed metastatic bone lesion of breast and lung cancer without serious complications. Together, 4-MU and hyaluronan oligosaccharides might be a promising novel therapeutic tools for metastatic bone disease.
|
Report
(4 results)
Research Products
(14 results)
